FDA
-
-
-
-
-
-
-
enGene reports 54% response rate in bladder cancer gene therapy trial
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Engene Holdings Inc. (ENGN)
-
-
-
-
-
-
-
enGene reports 62% response rate for bladder cancer treatment
-
-
-
-
-
-
-
enGene completes enrollment of 100 patients in bladder cancer trial
-
-
-
-
-
-
-
enGene Reports Second Quarter 2025 Financial Results and Provides Business Update
-
-
-
-
-
-
-
enGene Reports Full Year 2024 Financial Results and Provides a Business Update
-
-
-
323,570 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

